CytoPharm to Conduct Hepatitis C Trial and Seek Regulatory Approval for Amarillo Biosciences (AMAR)' Low Dose Oral Interferon
5/31/2007 1:05:33 PM
AMARILLO, TX -- (MARKET WIRE) -- May 31, 2007 -- Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that CytoPharm Inc., ABI's partner in Taiwan and China, has engaged a Clinical Research Organization (CRO) to conduct a clinical trial of 152 chronic hepatitis C patients. The patients, 38 per group, will receive one of three different dosages of oral human interferon alpha or placebo. The patients must have failed to respond to injectable interferon, or relapsed after initially responding to injectable interferon. The standard of care for chronic hepatitis C is high dose (millions of IU) of human interferon alpha injected alone or in combination with Ribavirin. Typically, only about 50% of hepatitis C patients respond to the standard of care. The trial is expected to start in the 4th quarter of 2007.
comments powered by